Curevac receives 300 million Euro for vaccination research

The German national bank KfW has invested 300 million Euro in the Tübingen enterprise Curevac, as told by the federal economics minister Peter Altmaier on Monday. The biotech-company is conducting research for a vaccination against the Corona virus in the Technologiepark Tübingen. Curevac wants to teach the human body how to produce its own vaccine. The enterprise wants to imitate a natural virus infection and, thus, activate the body’s own defence mechanisms. Press spokesman Thorsten Schüller explained the method to tünews INTERNATIONAL at the beginning of April. Meanwhile, Curevac has been allowed to test its vaccine in a clinical study with 170 volunteers. In spring, the biotech-company was already in the headlines: Supposedly, the US government was interested in the company and wanted an exclusive supply contract.

tun061603

Impressionen von der neuen Fieberamblanz des Landkreises Tübingen. Foto: tünews INTERNATIONAL; Mostafa Elyasian, 24.3.2020

Latest information on Corona: Click here

Related posts